TriangleNCT00025337 · CITED IN SOURCE DOCUMENTS
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2013-01-24
Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without bevacizumab in treating patients who have advanced or metastatic colorectal cancer that has been previously treated. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with combination chemotherapy may kill more tumor cells. It is not yet known if bevacizumab is more effective with or without combination chemotherapy in treating colorectal cancer
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Histologically confirmed adenocarcinoma of the colon or rectum * Advanced or metastatic disease * Must have received a fluoropyrimidine-based regimen and an irinotecan-based regimen, either alone or in combination, for advanced disease * May have relapsed within 6 months of adjuvant therapy with fluorouracil (5-FU) (or combination 5-FU and irinotecan) and progressed after single-agent irinotecan * Measurable disease * No known brain metastases * Performance status - ECOG 0-2 * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * No history of thrombotic or hemorrhagic disorders * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * AST no greater than 5 times ULN * INR no greater than 1.5 * PTT no greater than ULN * Creatinine no greater than 1.5 times ULN * Proteinuria less than 1+ (i.e., 0 or trace) * Protein less than 500 mg by 24-hour urine collection * Proteinuria secondary to ureteral stents allowed * No proteinuria secondary to nephropathy * Controlled hypertension (less than 150/100 mm Hg) allowed if on a stable antihypertensive regimen * No prior myocardial infarction * No uncontrolled congestive heart failure * No unstable angina within the past 3 months * No serious nonhealing wound, ulcer, or bone fracture * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No prior bevacizumab * See Disease Characteristics * Recovered from prior chemotherapy * No prior oxaliplatin * At least 2 weeks since prior radiotherapy and recovered * At least 28 days since prior major surgical procedure * At least 10 days since prior aspirin dose of more than 325 mg/day * No concurrent therapeutic anticoagulation except prophylactic anticoagulation of venous access device * No concurrent antiplatelet agents (e.g., dipyridamole, ticlopidine, clopidogrel, or cilostazol) * No concurrent oral cryotherapy on day 1 of oxaliplatin administration
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil (5-FU) IV over 22 hours on days 1 and 2.
- intervention Names
- Biological: bevacizumab
- Drug: oxaliplatin
- Drug: leucovorin calcium
- Drug: fluorouracil
- label
- Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)
- type
- EXPERIMENTAL
- description
- Patients receive oxaliplatin, leucovorin calcium, and 5-FU as in arm I.
- intervention Names
- Drug: oxaliplatin
- Drug: leucovorin calcium
- Drug: fluorouracil
- label
- Arm II (oxaliplatin, leucovorin calcium, fluorouracil)
- type
- EXPERIMENTAL
- description
- Patients receive bevacizumab as in arm I.
- intervention Names
- Biological: bevacizumab
- label
- Arm III (bevacizumab)
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)
- Arm III (bevacizumab)
- description
- Given IV
- name
- bevacizumab
- other Names
- anti-VEGF humanized monoclonal antibody
- anti-VEGF monoclonal antibody
- Avastin
- rhuMAb VEGF
- type
- BIOLOGICAL
- arm Group Labels
- Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)
- Arm II (oxaliplatin, leucovorin calcium, fluorouracil)
- description
- Given IV
- name
- oxaliplatin
- other Names
- 1-OHP
- Dacotin
- Dacplat
- Eloxatin
- L-OHP
- type
- DRUG
- arm Group Labels
- Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)
- Arm II (oxaliplatin, leucovorin calcium, fluorouracil)
- description
- Given IV
- name
- leucovorin calcium
- other Names
- CF
- CFR
- LV
- type
- DRUG
- arm Group Labels
- Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)
- Arm II (oxaliplatin, leucovorin calcium, fluorouracil)
- description
- Given IV
- name
- fluorouracil
- other Names
- 5-fluorouracil
- 5-Fluracil
- 5-FU
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 880
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- measure
- Overall survival
- time Frame
- From the date of entry on study, assessed up to 5 years
- secondary Outcomes
- measure
- Response defined using RECIST criteria
- time Frame
- Up to 5 years
- measure
- Progression free survival
- time Frame
- From the date of entry on the study to the appearance of new metastatic lesions or objective tumor progression, assessed up to 5 years
Full study description
- brief Summary
- Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without bevacizumab in treating patients who have advanced or metastatic colorectal cancer that has been previously treated. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with combination chemotherapy may kill more tumor cells. It is not yet known if bevacizumab is more effective with or without combination chemotherapy in treating colorectal cancer
- detailed Description
- OBJECTIVES: I. Compare the response, time to progression, and overall survival of patients with previously treated advanced or metastatic colorectal adenocarcinoma treated with oxaliplatin, leucovorin calcium, and fluorouracil with or without bevacizumab versus bevacizumab only. (Arm III closed to accrual as of 03/11/2003). II. Compare the toxicity of these regimens in these patients. OUTLINE: This is a randomized study. Patients are stratified according to ECOG performance status (0 vs 1 or 2), and prior radiotherapy (yes vs no). Patients are randomized to 1 of 3 treatment arms. Arm I: Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil (5-FU) IV over 22 hours on days 1 and 2. Arm II: Patients receive oxaliplatin, leucovorin calcium, and 5-FU as in arm I. Arm III: Patients receive bevacizumab as in arm I. (Arm closed to accrual as of 03/11/2003). Courses in all arms repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response may receive 2 additional courses. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-10a5d0fac2e470dccd8d
- requested nct id
- NCT00025337
- primary nct id
- NCT00025337
- source kind
- fda_spl_label
- source record id
- 2644fd0e-5b94-9120-bdb1-e275d982b249
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- payload sha256
- 9efed0ddb4b21741ab8939635205e0e157aa00078ad06ae91c90d6604c143085
- payload
- application numbers
- BLA761175
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-10a5d0fac2e470dccd8d
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00025337
- occurrences
- context exact
- orectal Cancer in Study AVF2107g Study E3200 The safety and efficacy of bevacizumab were evaluated in a randomized, open-label, active-controlled study [E3200 (NCT00025337)] in 829 patients who were previously treated with irinotecan and fluorouracil for initial therapy for metastatic disease or as adjuvant therapy. Patients were
- end
- 2395
- exact text
- NCT00025337
- start
- 2384
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00100.json
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source json pointer
- /results/34/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 2644fd0e-5b94-9120-bdb1-e275d982b249
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- e21069a0948bbce06a85786ddbbc2839d4f9236f5865abba3e3379c45bd1d271
- spl effective time
- 20260311
- spl set id
- 70ab1de6-fb68-aee4-a6cb-f9a0f146687f
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-849e5fce32d64e99e91e
- requested nct id
- NCT00025337
- primary nct id
- NCT00025337
- source kind
- fda_spl_label
- source record id
- 598b7687-6daa-2ce7-e063-6394a90ab429
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 717f1014e54e67476fed665f771f5147da7ec552c57de6b1f9fed5042eabde98
- payload
- application numbers
- BLA761268
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-849e5fce32d64e99e91e
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00025337
- occurrences
- context exact
- sponse was 8.5 months. Figure 1 Study E3200 The safety and efficacy of bevacizumab were evaluated in a randomized, open-label, active-controlled study [E3200 ( NCT00025337 )] in 829 patients who were previously treated with irinotecan and fluorouracil for initial therapy for metastatic disease or as adjuvant therapy. Patients wer
- end
- 2297
- exact text
- NCT00025337
- start
- 2286
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/78/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 598b7687-6daa-2ce7-e063-6394a90ab429
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 20f4d916b986722fb555e4c9410051bc1746100f6c73529af41036961c7d881c
- spl effective time
- 20260821
- spl set id
- 4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-9478ed50bcb7d226f7e6
- requested nct id
- NCT00025337
- primary nct id
- NCT00025337
- source kind
- fda_spl_label
- source record id
- 8debebf6-af94-4ba7-8d67-c801f4ea27eb
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- payload sha256
- 9ccbc99fa3d98b1d5d4ff90a1f8b89f869a8fbfe2cc7a969845e21ee21eb77a8
- payload
- application numbers
- BLA125085
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-9478ed50bcb7d226f7e6
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00025337
- occurrences
- context exact
- of response was 8.5 months. Figure 1 Study E3200 The safety and efficacy of Avastin were evaluated in a randomized, open-label, active-controlled study [E3200 (NCT00025337)] in 829 patients who were previously treated with irinotecan and fluorouracil for initial therapy for metastatic disease or as adjuvant therapy. Patients were
- end
- 2261
- exact text
- NCT00025337
- start
- 2250
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00500.json
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source json pointer
- /results/24/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 8debebf6-af94-4ba7-8d67-c801f4ea27eb
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 6f9f86027b6f32969be7f30286f48e96e380fd91a3cb2490b51001f709a7db71
- spl effective time
- 20250106
- spl set id
- 939b5d1f-9fb2-4499-80ef-0607aa6b114e
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-a017e26fb05c90e1215e
- requested nct id
- NCT00025337
- primary nct id
- NCT00025337
- source kind
- fda_spl_label
- source record id
- 25c471d4-a4c1-4f99-8848-c49ce5b0000a
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- payload sha256
- e0216c46bf2e263be2a2ecdf6470f816e79e73f4673e4e42ea4d65a58bab4ca1
- payload
- application numbers
- BLA761231
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-a017e26fb05c90e1215e
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00025337
- occurrences
- context exact
- tion of response was 8.5 months. Study E3200 The safety and efficacy of bevacizumab were evaluated in a randomized, open-label, active-controlled study [E3200 (NCT00025337)] in 829 patients who were previously treated with irinotecan and fluorouracil for initial therapy for metastatic disease or as adjuvant therapy. Patients were
- end
- 2294
- exact text
- NCT00025337
- start
- 2283
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00100.json
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source json pointer
- /results/32/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 25c471d4-a4c1-4f99-8848-c49ce5b0000a
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 5661fdb9074fbb034143e12e4a4605083cbd33b4e3098809cb7343109493185d
- spl effective time
- 20260127
- spl set id
- 42b4f96e-1f70-2126-e063-6294a90a93e3
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-b4169b2c6c59daa5f5ca
- requested nct id
- NCT00025337
- primary nct id
- NCT00025337
- source kind
- fda_spl_label
- source record id
- ea079b8e-24b7-4e03-8340-8078f30f6d98
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- payload sha256
- 9c3646df0156189211d5dd4073615900ac13e55aa297b5e13bb43dbf118cb9c7
- payload
- application numbers
- BLA761028
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-b4169b2c6c59daa5f5ca
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00025337
- occurrences
- context exact
- esponse was 8.5 months. Figure 1 Study E3200 The safety and efficacy of bevacizumab were evaluated in a randomized, open-label, active-controlled study [E3200 (NCT00025337)] in 829 patients who were previously treated with irinotecan and fluorouracil for initial therapy for metastatic disease or as adjuvant therapy. Patients were
- end
- 2302
- exact text
- NCT00025337
- start
- 2291
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00700.json
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source json pointer
- /results/79/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- ea079b8e-24b7-4e03-8340-8078f30f6d98
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- bbf2f2af7cb8babda09095a78b354d15a500aba442759b04c1595566b0870385
- spl effective time
- 20260623
- spl set id
- 0a562b4e-67ce-4bab-852c-d9ee71e55fb8
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-b557b947c661598a3dec
- requested nct id
- NCT00025337
- primary nct id
- NCT00025337
- source kind
- fda_spl_label
- source record id
- 8f385b9e-2699-46a0-8c5f-ec1d86cd609d
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- payload sha256
- a75be205d7ec55f451b5a581d1972daa391401a33d87d39194f614eb3cb9c26b
- payload
- application numbers
- BLA761099
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-b557b947c661598a3dec
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00025337
- occurrences
- context exact
- esponse was 8.5 months. Figure 1 Study E3200 The safety and efficacy of bevacizumab were evaluated in a randomized, open-label, active-controlled study [E3200 (NCT00025337)] in 829 patients who were previously treated with irinotecan and fluorouracil for initial therapy for metastatic disease or as adjuvant therapy. Patients were
- end
- 2296
- exact text
- NCT00025337
- start
- 2285
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00500.json
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source json pointer
- /results/27/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 8f385b9e-2699-46a0-8c5f-ec1d86cd609d
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 774cfec5b812453dac521297deff828caeb90e4c09011e2ec66273f66c607f0b
- spl effective time
- 20260721
- spl set id
- aa27acbd-d117-4350-aeee-17bc2e2c0ca4
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-dad213dba9d6af26c0ed
- requested nct id
- NCT00025337
- primary nct id
- NCT00025337
- source kind
- fda_spl_label
- source record id
- ca8057b2-9aec-43bc-8525-cf8091433c71
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- af1b6007226594af8ca0f78e91ea805a9651c4df1b8e5837a7b16790af2fcf60
- payload
- application numbers
- BLA761231
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-dad213dba9d6af26c0ed
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00025337
- occurrences
- context exact
- tion of response was 8.5 months. Study E3200 The safety and efficacy of bevacizumab were evaluated in a randomized, open-label, active-controlled study [E3200 (NCT00025337)] in 829 patients who were previously treated with irinotecan and fluorouracil for initial therapy for metastatic disease or as adjuvant therapy. Patients were
- end
- 2294
- exact text
- NCT00025337
- start
- 2283
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/67/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- ca8057b2-9aec-43bc-8525-cf8091433c71
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 5661fdb9074fbb034143e12e4a4605083cbd33b4e3098809cb7343109493185d
- spl effective time
- 20260323
- spl set id
- 6b4040a2-a5c5-4ff0-ab45-935d7e49cf78
Preserved source evidence · Not medical advice